FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a report published on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reissued a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Price Performance

FGEN stock opened at $0.42 on Friday. The company has a market capitalization of $42.42 million, a P/E ratio of -0.34 and a beta of 0.72. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.93. The firm’s fifty day simple moving average is $0.36 and its 200-day simple moving average is $0.64.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the previous year, the company posted ($0.52) earnings per share. As a group, sell-side analysts forecast that FibroGen will post -0.86 earnings per share for the current year.

Institutional Trading of FibroGen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 DIFC Ltd raised its position in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 45,990 shares during the period. Doheny Asset Management CA acquired a new position in FibroGen in the 2nd quarter worth about $48,000. Accel Wealth Management boosted its position in FibroGen by 117.5% during the second quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 51,645 shares in the last quarter. Franklin Street Advisors Inc. NC acquired a new stake in FibroGen in the second quarter valued at approximately $89,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in FibroGen in the second quarter valued at approximately $130,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.